Reviving hopes for its experimental dendritic cell-based vaccine, ICT-107, Immunocellular Therapeutics Ltd. said it expects to soon begin enrolling newly diagnosed glioblastoma patients in a registrational phase III trial under a special protocol assessment (SPA) freshly agreed with the FDA.